Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.05B |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.61B |
| 3 |
Tesla
TSLA
|
+$636M |
| 4 |
TSMC
TSM
|
+$604M |
| 5 |
iShares Bitcoin Trust
IBIT
|
+$330M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.25B |
| 2 |
Apple
AAPL
|
+$1.13B |
| 3 |
Microsoft
MSFT
|
+$988M |
| 4 |
Meta Platforms (Facebook)
META
|
+$572M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$570M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 1.55% |
| 2 | Consumer Discretionary | 0.95% |
| 3 | Financials | 0.77% |
| 4 | Healthcare | 0.67% |
| 5 | Industrials | 0.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
11876
CALL
Ring Energy
REI
$367M
| $48.6K | ﹤0.01% |
+42,300
| New | +$55.2K |
|
|
ZEPP
11877
PUT
Zepp Health
ZEPP
$75.7M
| $48.5K | ﹤0.01% |
+16,400
| New | +$48.9K |
|
|
HIX
11878
Western Asset High Income Fund II
HIX
$351M
| $48.1K | ﹤0.01% |
+11,507
| New | +$49.5K |
|
11879
Werewolf Therapeutics
HOWL
$44.7M
| $48K | ﹤0.01% |
49,341
+15,479
| +46% | +$20.3K |
|
11880
Cocrystal Pharma
COCP
$21.6M
| $47.8K | ﹤0.01% |
33,683
+21,556
| +178% | +$40.2K |
|
11881
CALL
AbCellera Biologics
ABCL
$3.92B
| $47.7K | ﹤0.01% |
21,400
-13,300
| -38% | -$38.1K |
|
11882
PUT
Wheels Up
UP
$191M
| $47.7K | ﹤0.01% |
2,360
+1,355
| +135% | +$37.3K |
|
11883
TOMI Environmental Solutions
TOMZ
$13.9M
| $46.9K | ﹤0.01% |
19,051
+4,235
| +29% | +$11.9K |
|
|
SIFY
11884
Sify Technologies
SIFY
$1.05B
| $46.8K | ﹤0.01% |
10,934
-4,541
| -29% | -$18.1K |
|
11885
Sono-Tek
SOTK
$81.6M
| $46.6K | ﹤0.01% |
12,806
+560
| +5% | +$2.15K |
|
|
AKYA
11886
DELISTED
Akoya BioSciences
AKYA
| $46.6K | ﹤0.01% |
33,530
-8,022
| -19% | -$17.6K |
|
11887
Altisource Portfolio Solutions
ASPS
$67.4M
| $46.4K | ﹤0.01% |
8,526
+3,660
| +75% | +$22.5K |
|
11888
CALL
Aclaris Therapeutics
ACRS
$921M
| $46.4K | ﹤0.01% |
30,300
-200,000
| -87% | -$427K |
|
|
ZJYL
11889
Jin Medical International
ZJYL
$207M
| $46.4K | ﹤0.01% |
+3,118
| New | +$51.9K |
|
11890
CALL
RAVE Restaurant Group
RAVE
$44.8M
| $45.9K | ﹤0.01% |
16,700
-14,100
| -46% | -$37.7K |
|
11891
CALL
GSI Technology
GSIT
$224M
| $45.9K | ﹤0.01% |
22,600
+6,500
| +40% | +$19K |
|
|
SRG
11892
CALL
Seritage Growth Properties
SRG
$119M
| $45.9K | ﹤0.01% |
14,200
-128,500
| -90% | -$471K |
|
11893
PUT
Relay Therapeutics
RLAY
$4.28B
| $45.9K | ﹤0.01% |
17,500
+6,300
| +56% | +$24.7K |
|
11894
Solarmax Technology
SMXT
$13.8M
| $45.8K | ﹤0.01% |
3,183
+2,129
| +202% | +$36.6K |
|
|
CASI
11895
DELISTED
CASI Pharmaceuticals
CASI
| $45.7K | ﹤0.01% |
+21,143
| New | +$51.7K |
|
|
BHR
11896
PUT
Braemar Hotels & Resorts
BHR
$140M
| $45.6K | ﹤0.01% |
+18,300
| New | +$50K |
|
11897
Metagenomi Therapeutics
MGX
$46.1M
| $45.2K | ﹤0.01% |
33,250
+21,438
| +181% | +$51.1K |
|
11898
CALL
Savara
SVRA
$1.15B
| $45.2K | ﹤0.01% |
16,300
-3,600
| -18% | -$9.94K |
|
|
HURA
11899
TuHURA Biosciences
HURA
$133M
| $44.6K | ﹤0.01% |
+13,798
| New | +$50.9K |
|
11900
LiveWire
LVWR
$294M
| $44.5K | ﹤0.01% |
+22,232
| New | +$64.8K |
|
Similar funds
Jeff Yass's Q1 2025 Portfolio in Review
As of Q1 2025, Jeff Yass held 13,842 positions worth $586B, down 12% from $663B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Jeff Yass withdrew a net $24.4B in Q1 2025, closing 1,482 positions and reducing 4,842 holdings. Its most notable exit was Inari Medical, Inc. Common Stock, an estimated $24M position sold in full.
By sector, the portfolio is most concentrated in Technology at 1.6% of assets, down from 2% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, Jeff Yass opened a new position in Brookfield Asset Management worth $86M.
- Jeff Yass's largest Q1 2025 buy was Brookfield Asset Management: 1,775,684 shares worth $86M.
- Jeff Yass added most to State Street SPDR S&P 500 ETF Trust in Q1 2025, an estimated $4.05B increase.
- Jeff Yass's biggest Q1 2025 reduction was Invesco QQQ Trust, cutting an estimated $1.25B.
- Jeff Yass fully exited Inari Medical, Inc. Common Stock in Q1 2025, selling an estimated $24M.
- Jeff Yass's ten largest holdings make up 28% of its $586B portfolio in Q1 2025.
- Jeff Yass opened 1,775 new positions and closed 1,482 in Q1 2025.
- Jeff Yass's portfolio value fell 12% quarter-over-quarter to $586B.
Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.